Background: Fragile histidine triad (FHIT) gene is a tumor suppressor gene which involved in breast cancerpathogenesis. Epigenetics alterations in FHIT contributes to tumorigenesis of breast cancer. Objective: Ourobjective was to study FHIT promoter region hypermethylation in Egyptian breast cancer patients and itsassociation with clinicopathological features. Materials and Methods: Methylation-specific polymerase chainreaction was performed to study the hypermethylation of FHIT promoter region in 20 benign breast tissues and30 breast cancer tissues. Results: The frequency of hypermethylation of FHIT promoter region was significantlyincreased in breast cancer patients compared to bengin breast disease patients. The Odd´s ratio (95%CI) ofdevelopment of breast cancer in individuals with FHIT promoter hypermethylation (MM) was 11.0 (1.22-250.8).There were also significant associations between FHIT promoter hypermethylation and estrogen, progesteronereceptors negativity, tumor stage and nodal involvment in breast cancer pateints. Conclusions: Our resultssupport an association between FHIT promotor hypermethylation and development of breast cancer in Egyptianbreast cancer patients. FHIT promoter hypermethylation is associated with some poor prognostic features ofbreast cancer.
(2015). Analysis of FHIT Gene Methylation in Egyptian Breast Cancer Women: Association with Clinicopathological Features. Asian Pacific Journal of Cancer Prevention, 16(3), 1235-1239.
MLA
. "Analysis of FHIT Gene Methylation in Egyptian Breast Cancer Women: Association with Clinicopathological Features". Asian Pacific Journal of Cancer Prevention, 16, 3, 2015, 1235-1239.
HARVARD
(2015). 'Analysis of FHIT Gene Methylation in Egyptian Breast Cancer Women: Association with Clinicopathological Features', Asian Pacific Journal of Cancer Prevention, 16(3), pp. 1235-1239.
VANCOUVER
Analysis of FHIT Gene Methylation in Egyptian Breast Cancer Women: Association with Clinicopathological Features. Asian Pacific Journal of Cancer Prevention, 2015; 16(3): 1235-1239.